Pharmacotherapeutic management of breakthrough pain in patients with chronic persistent pain

American Journal of Managed Care

Volumn 14, Issue SUPPL. 4, 2008, Pages

  Fishbain, David A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; FENTANYL; FENTANYL CITRATE; METHADONE; MIDAZOLAM; MORPHINE; SUFENTANIL;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ANEMIA; ANOREXIA; ANXIETY; APPLICATION SITE DISCOMFORT; ARTHRALGIA; ASTHENIA; BACKACHE; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG FORMULATION; DYSPNEA; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; HYPOKALEMIA; INSOMNIA; NAUSEA; NEUTROPENIA; PAIN; PATIENT SATISFACTION; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; ULCER; VOMITING; WEIGHT CHANGE;

ANALGESICS, OPIOID; CHRONIC DISEASE; FENTANYL; HUMANS; PAIN;

EID: 44649124854     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Chou R, Clark E, Helfend M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage. 2003;26:1026-1048.
2. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-811.
3. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2: management. Pharm Ther. 2005;30:354-361.
4. McCarberg BH. The treatment of breakthrough pain. Pain Med. 2007;8:S8-S13.
5. Molton IR, Graham C, Stoelb BL, Jensen MP. Current psychological approaches to the management of chronic pain. Curr Opin Anaesthesiol. 2007;20:485-489.
6. Walker G, Wilcock A, Manderson C, Weller R, Crosby V. The acceptability of different routes of administration of analgesia for breakthrough pain. J Palliat Med. 2003;17:219-221.
7. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611-616.
8. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-281.
9. Portenoy RK, Payne R, Coluzzi R et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999;79:303-312.
10. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123-130.
11. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:588-601.
12. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin. 2007;23:223-233.
13. Fentora [package insert]. Eden Prairie, MN: CIMA Labs Inc; and Salt Lake City, UT: Cephalon, Inc; 2006.
14. Blick SK, Wagstaff AJ. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs. 2006;66:2387-2395.
15. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327-334.
16. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998;16:3238-3245.
17. Hagen NA, Fisher K, Victorino C, Farrar JT. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med. 2007;10:47-55.
18. Aronoff GM, Brennan MJ, Pritehard DD, Ginsberg B. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med. 2005;6: 305-314.
19. Rauck R, Segal T, Taylor DR, Messina J. Long-term safety of fentanyl effervescent buccal tablets: interim analysis in patients with cancer-related breakthrough pain. Presented at American Academy of Pain Medicine's Annual Meeting; February 22-25, 2006; San Diego, CA. Poster 159.
20. Hale ME, Webster L, Peppin J, Messina J. Open-label study of fentanyl effervescent buccal tablets in patients with chronic pain and breakthrough pain: interim safety results. Presented at: American Academy of Pain Medicine's Annual Meeting; February 22-25, 2006; San Diego, CA. Poster 120.
21. Actiq [package insert]. Salt Lake City, UT: Cephalon, Inc; 2006.
22. del Rosario MA, Martin AS, Ortega JJ, Feria M. Temporary sedation with midazolam for control of severe incident pain. J Pain Symptom Manage. 2001;21:439-442.
23. Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004;108:17-27.
24. Parlow JL, Milne B, Tod DA, Stewart GI, Griffiths JM, Dudgeon DJ. Self-administered nitrous oxide for the management of incident pain in terminally ill patients: a blinded case series. Palliat Med. 2005;19:3-8.
25. Fisher K, Stiles C, Hagen NA. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage. 2004;28:619-625.
26. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25: 150-168.
27. Duncan A. The use of fentanyl and alfentanil sprays for episodic pain. Palliat Med. 2002;16:550.
28. Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med. 2000;14:57-58.
29. Pavis H, Wilcock A, Edgecombe J, et al. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer. J Pain Symptom Manage. 2002;24:598-602.
30. Fitzgibbon D, Morgan D, Dockter D, Barry C, Kharasch ED. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain. 2003;106:309-315.
31. Jackson K, Ashby M, Keech J. Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain. J Pain Symptom Manage. 2002;23:450-452.
32. Gardner-Nix J. Oral transmucosal fentanyl and sufentanil for incident pain. J Pain Symptom Manage. 2001;22:627-630.
33. Kunz KM, Theisen JA, Schroeder ME. Severe episodic pain: management with sublingual sufentanil. J Pain Symptom Manage. 1993;8:189-190.
34. Hagen NA, Fisher K, Stiles C. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. J Palliat Med. 2007;10:331-337.
35. Enting RH, Mucchiano C, Oldenmenger WH, et al. The "pain pen" for breakthrough cancer pain: a promising treatment. J Pain Symptom Manage. 2005;29: 213-217.
36. Mercadante S, Villari P, Ferrera R et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage. 2006;32:175-179.
37. Douglass B. BEMA fentanyl demonstrates substantial transmucosal delivery. http://www.medicalnewstoday.com/articles/70251.php. Accessed October 3, 2007.
38. Kirsch KL, Whitcomb LA, Donaghy K, Passik SD. Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study. Clin J Pain. 2002;18:S52-S60.
39. Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007;129:355-362.
40. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6:432-442.
41. Akbik H, Butler SF, Budman SH, Fernandez K, Katz N, Jamison RN. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage. 2006;32:287-293.
42. Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med. 2004;5:309-324.
43. Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. http://www.pain policy.wisc.edu/domestic/model04.pdf. Accessed October 15, 2007.
44. Atluri S, Boswell MV, Hansen HC, Trescot AM, Singh V, Jordan AE. Guidelines for the use of controlled substances in the management of chronic pain. Pain Physician. 2003;6:233-257.
45. Katz NP, Sherburne S, Beach M, et al. Behavior monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97:1097-1102.
46. Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med. 2007;8:281-288.